A venture-backed biotech company, IFM Therapeutics is into developing therapies that regulate novel targets in the innate immune system for the treatment of cancer, autoimmunity and inflammatory disorders.
Marketed as Tecentriq, atezolizumab was assessed by NICE as a treatment option for patients with advanced urothelial cancer. The UK drug watchdog has suggested Roche to file a
Opdivo which has to be injected intravenously has been approved for treating mCRC patients whose disease is in the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) form.
The transaction will help LabCorp create leading expertise in the oncology segment by combining the extensive experience of Covance in late phase with the deep expertise of Chiltern
Maviret is intended to be taken daily once for eight weeks. It is free from ribavirin and is a pan-genotypic treatment for patients not suffering from cirrhosis and
PFS is one of the three primary endpoints in the randomised, open-label, multi-centre, global trial, dubbed MYSTIC, which compared Imfinzi as a monotherapy or in combination with tremelimumab
The British pharma giant also said that it is weighing options for its Rare Diseases business which it is looking to divest in the near future following a
The trial dubbed KEYNOTE-040 was held in patients who had previously undergone treatment for HNSCC and whose disease had recurred or is in a metastatic stage. While the
The deal will help MTPC grow its product pipeline in the central nervous system disease area. The company intends to offer patients with innovative drugs for unmet medical needs.
IBM scientists and the University of Alberta in Edmonton, Canada, have published new data in Nature's partner journal. The research was on computational psychiatry which uses AI to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.